Treatment outcomes for patients with newly diagnosed or relapsed/refractory TP53-mutated mantle cell lymphoma: a systematic review and meta-analysis ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

A new study by researchers at Karolinska Institutet and Karolinska University Hospital shows that patients diagnosed with the ...

An agent that may fulfill these requirements is the glycan-binding protein Galectin-9 (Gal-9). Indeed, treatment with Gal-9 reduced total cell counts and cell viability of various B cell NHL cell ...

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma ...

A new study shows that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic ...

B-cell lymphomas, which tend to be nodal based, are the more common type, and only rarely have cutaneous manifestations. In contrast, however, T-cell lymphomas commonly manifest in the skin.

Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Columvi U.S. Indication ...

Real-world experience with dose-adjusted EPOCH-R in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma: A multicenter analysis from Turkey.. If you have the appropriate software ...